Mittie Doyle is Chief Medical Officer at Avalo Therapeutics, Inc. (AVTX). They have made 1 open-market trade across 1 company since 2026, most recently 2026-08-28.
CIK 0001918845
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AVTX | 51,776 | $584K |
Shares reported on the most recent Form 4, priced at the 2026-09-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AVTX | SELL · 10b5-1 | 2026-08-28 | 2026-09-01 | $20.00 | $14K | -16.7% | -23.0% | — |
| AVTX | SELL · 10b5-1 | 2026-08-17 | 2026-08-19 | $20.00 | $20K | -5.3% | -18.5% | — |
| AVTX | SELL · 10b5-1 | 2026-08-10 | 2026-08-12 | $20.00 | $14K | -1.5% | -17.6% | — |
| AVTX | SELL · 10b5-1 | 2026-07-27 | 2026-07-29 | $20.00 | $20K | +1.6% | +0.8% | — |
| AVTX | SELL · 10b5-1 | 2026-06-30 | 2026-07-02 | $20.00 | $93K | -3.5% | -6.1% | -20.3% |
| AVTX | SELL · 10b5-1 | 2026-06-23 | 2026-06-25 | $18.00 | $26K | +4.9% | +6.7% | -16.4% |
| AVTX | SELL · 10b5-1 | 2026-05-28 | 2026-06-01 | $16.00 | $11K | -11.1% | +12.5% | +25.5% |
| AVTX | SELL · 10b5-1 | 2026-05-15 | 2026-05-19 | $18.76 | $56K | -3.5% | -9.9% | +22.1% |
| AVTX | SELL · 10b5-1 | 2026-05-05 | 2026-05-07 | $20.61 | $2.2M | -28.5% | -44.1% | -17.1% |
| AVTX | SELL · 10b5-1 | 2026-04-06 | 2026-04-08 | $18.01 | $72K | -0.7% | +45.8% | +30.3% |
| AVTX | SELL · 10b5-1 | 2026-04-01 | 2026-04-03 | $16.00 | $11K | -26.3% | -23.9% | +4.2% |
| AVTX | SELL | 2026-03-16 | 2026-03-18 | $16.15 | $823K | -2.6% | +0.9% | +0.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.